Resting Energy Expenditure in Palliative Cancer Patients (REPAT)
June 26, 2026 updated by: Norwegian University of Science and Technology
Resting Energy Expenditure in Palliative Cancer Patients (REPAT) - an Explorative Study in Patients With Incurable Cancer
The study purpose is to measure REE by indirect calorimetry and to determine limits of agreement with confidence intervals between measured REE and predictive equations for determination of energy requirements in patients with incurable cancer.
Clinical factors associated with hyper- and hypometabolism will be elucidated.
Data will be obtained from patient journals in combination with measurements of REE and registration of survival.
Data will be collected at one timepoint and survival will be monitored prospectively.
Study Overview
Study Type
Observational
Enrollment (Actual)
160
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Trondheim, Norway, 7021
- Cancer Clinic, St. Olavs Hospital, Trondheim University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
The population is patients diagnosed with an incurable malignant disease and hospitalized at the cancer clinic, St. Olavs Hospital in the period from september 2023 to june 2026.
They have to be 18 years or older and able to provide written informed consent and comply with all study procedures.
Description
Inclusion Criteria:
- A verified diagnosis of an incurable malignant disease
- Hospitalized at the Cancer clinic, St. Olavs Hospital
- ≥ 18 years of age
- Able to provide written informed consent
- Able to comply with all study procedures
Exclusion Criteria:
- Cognitive impairment
- In need of supplementary oxygen
- Receiving invasive or noninvasive ventilation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Measurement of resting energy expenditure (REE) in patients with incurable cancer measured with the COSMED Q-NRG+ Indirect Calorimeter with a Canopy Hood.
Time Frame: Throughout study completion, approximately 3 years.
|
Investigate the agreement between the most used energy expenditure prediction equation (Harris-Benedict calculation for resting energy expenditure based on weight, height and gender) and measured REE (kilocalories/day) by indirect calorimetry in patients with incurable cancer.
|
Throughout study completion, approximately 3 years.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical factors associated with hyper- and hypometabolism
Time Frame: Throughout study completion, approximately 3 years.
|
Explore the association between patients identified as hyper-or hypometabolic (REE > 10% or < 10% of the predicted BMR (in kilocalories per day)) and a set of explanatory variables such as cancer diagnosis (type), weight loss last six months ((current/past weight)*100), symptom score (Edmonton Symptom Assessment System (ESAS)), degree of inflammation (CRP in mg/L), and survival (days after REE measurement).
|
Throughout study completion, approximately 3 years.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 5, 2023
Primary Completion (Actual)
September 23, 2025
Study Completion (Estimated)
September 30, 2026
Study Registration Dates
First Submitted
December 14, 2023
First Submitted That Met QC Criteria
January 4, 2024
First Posted (Actual)
January 16, 2024
Study Record Updates
Last Update Posted (Actual)
June 29, 2026
Last Update Submitted That Met QC Criteria
June 26, 2026
Last Verified
June 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 622545
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.